Literature DB >> 3120094

Acute viral laryngotracheitis complicated by herpes simplex virus infection.

J B Harris1, R Lusk, J S Wagener, R D Andersen.   

Abstract

We report the development of HSV-1 laryngotracheitis during the resolution phase of typical viral laryngotracheobronchitis (LTB) in an infant. This case represents an uncommon complication of viral LTB which has previously been described only at autopsy and suggests that prolonged use of systemic corticosteroids may lead to secondary infections, such as HSV-1. Therefore, we recommend that corticosteroid therapy for LTB be limited to 48 degrees in duration. This case also demonstrates that when an atypical clinical course is being followed by a patient who has LTB, then early diagnostic intervention is indicated. If HSV-1 is identified, anti-viral chemotherapy should be initiated and artificial airway management may be necessary. Tracheal intubation may be used, but, if extensive subglottic ulceration occurs, the subglottis should be bypassed in order that the chance of subglottic stenosis be minimized. In this case, early identification by bronchoscopy and viral cultures resulted in a successful combined medical-surgical management and total resolution with no sequelae.

Entities:  

Mesh:

Year:  1987        PMID: 3120094     DOI: 10.1177/019459988709600213

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

1.  A case of atypical croup.

Authors:  Geoff Cuvelier; Amged El-Hawrani; Hamdy El-Hakim; Joan L Robinson
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-11       Impact factor: 2.471

2.  Severe upper airway obstruction caused by ulcerative laryngitis.

Authors:  M Hatherill; L Reynolds; Z Waggie; A Argent
Journal:  Arch Dis Child       Date:  2001-10       Impact factor: 3.791

3.  Defining atypical croup: A case report and review of the literature.

Authors:  Raphael Hanna; Francisco Lee; Derek Drummond; Warren K Yunker
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-09-17       Impact factor: 1.675

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.